{"id":"W4365512159","doi":"10.1158/1538-7445.am2023-ct160","title":"Abstract CT160: Phase 1b/2a clinical trial of the oral BET inhibitor PLX2853 as monotherapy for ARID1A mutated gynecologic cancers and in combination with carboplatin for platinum resistant ovarian cance","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bromodomain; Medicine; Carboplatin; Tolerability; BET inhibitor; Combination therapy; Internal medicine; Ovarian cancer; Phases of clinical research; Oncology; BRD4; Cancer; Gynecologic oncology; Endometrial cancer; Clinical trial; Pharmacology; Chemotherapy; Adverse effect; Epigenetics; Cisplatin; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001386218,0.0022273,0.001881782,0.0007983293,0.000538493,0.001202971,0.001256432,0.002251919,0.01079717],"category_scores_gemma":[0.0008263765,0.000747283,0.001194671,0.0005599431,0.001166473,0.001067055,0.000450463,0.003832216,0.002196958],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001285776,"about_ca_system_score_gemma":0.002156569,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001283239,"about_ca_topic_score_gemma":0.003314471,"domain_scores_codex":[0.9996829,0.0001289961,0.00001617834,0.00005921433,0.00003961452,0.00007313966],"domain_scores_gemma":[0.9994629,0.00005914751,0.00009886895,0.00004641555,0.00003780257,0.0002948907],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.681486,0.08497105,0.004047606,0.001595874,0.000858873,0.0005771911,0.0003178097,0.00303086,0.1198242,0.001084019,0.01787164,0.08433501],"study_design_scores_gemma":[0.6011931,0.3809252,0.004557977,0.00006638334,0.000202954,0.0003058876,0.00005656374,0.001098664,0.00583151,0.0002918581,0.005437572,0.00003240416],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9710591,0.002775806,0.0007266077,0.001160508,0.0002739751,0.00837185,0.007096385,0.000420092,0.008115568],"genre_scores_gemma":[0.9491466,0.002812073,0.003368137,0.002594359,0.0003999653,0.009655251,0.01332438,0.000114127,0.01858514],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01079717,"threshold_uncertainty_score":0.03612012,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1053872898490996,"score_gpt":0.4546641015727174,"score_spread":0.3492768117236177,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}